[go: up one dir, main page]

EP1381598A4 - Nouveaux inhibiteurs de la tyrosine kinase - Google Patents

Nouveaux inhibiteurs de la tyrosine kinase

Info

Publication number
EP1381598A4
EP1381598A4 EP02723631A EP02723631A EP1381598A4 EP 1381598 A4 EP1381598 A4 EP 1381598A4 EP 02723631 A EP02723631 A EP 02723631A EP 02723631 A EP02723631 A EP 02723631A EP 1381598 A4 EP1381598 A4 EP 1381598A4
Authority
EP
European Patent Office
Prior art keywords
tyrosine kinase
kinase inhibitors
novel tyrosine
novel
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02723631A
Other languages
German (de)
English (en)
Other versions
EP1381598A1 (fr
Inventor
Mark D Wittman
Neelakantan Balasubramanian
Upender Velaparthi
Kurt Zimmermann
Mark G Saulnier
Peiying Liu
Xiaopeng Sang
David B Frennesson
Karen M Stoffan
James G Tarrant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1381598A1 publication Critical patent/EP1381598A1/fr
Publication of EP1381598A4 publication Critical patent/EP1381598A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02723631A 2001-03-28 2002-03-26 Nouveaux inhibiteurs de la tyrosine kinase Withdrawn EP1381598A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28
US279327P 2001-03-28
PCT/US2002/009402 WO2002079192A1 (fr) 2001-03-28 2002-03-26 Nouveaux inhibiteurs de la tyrosine kinase

Publications (2)

Publication Number Publication Date
EP1381598A1 EP1381598A1 (fr) 2004-01-21
EP1381598A4 true EP1381598A4 (fr) 2008-03-19

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02723631A Withdrawn EP1381598A4 (fr) 2001-03-28 2002-03-26 Nouveaux inhibiteurs de la tyrosine kinase

Country Status (25)

Country Link
EP (1) EP1381598A4 (fr)
JP (1) JP2004534010A (fr)
KR (1) KR20030083016A (fr)
CN (1) CN1514833A (fr)
AR (1) AR035804A1 (fr)
BG (1) BG108206A (fr)
BR (1) BR0208373A (fr)
CA (1) CA2442428A1 (fr)
CZ (1) CZ20032615A3 (fr)
EE (1) EE200300475A (fr)
GE (1) GEP20053660B (fr)
HR (1) HRP20030844A2 (fr)
HU (1) HUP0400323A2 (fr)
IL (1) IL158041A0 (fr)
IS (1) IS6968A (fr)
MX (1) MXPA03008690A (fr)
NO (1) NO20034308L (fr)
PE (1) PE20021015A1 (fr)
PL (1) PL373300A1 (fr)
RU (1) RU2003131693A (fr)
SK (1) SK12002003A3 (fr)
UY (1) UY27234A1 (fr)
WO (1) WO2002079192A1 (fr)
YU (1) YU84603A (fr)
ZA (1) ZA200307466B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
JP2005518800A (ja) 2002-03-01 2005-06-30 ブリストル−マイヤーズ　スクイブ　カンパニー 構成的に活性化されたチロシンキナーゼレセプターを発現するトランスジェニック非ヒト哺乳動物
US6921821B2 (en) * 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
US7361691B2 (en) * 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
EP1581539A4 (fr) * 2003-01-03 2007-09-19 Bristol Myers Squibb Co Nouveaux inhibiteurs de tyrosine kinase
JP2006516626A (ja) * 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
AP2139A (en) 2004-04-02 2010-08-21 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
KR20070095952A (ko) * 2004-12-16 2007-10-01 버텍스 파마슈티칼스 인코포레이티드 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
WO2006130657A2 (fr) 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Procede de reduction stereoselective pour la preparation de composes de pyrrolotriazine
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP2468752A1 (fr) 2005-08-04 2012-06-27 Sirtris Pharmaceuticals, Inc. Dérivés de thiazolopyridine comme modulateurs de sirtuine
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2620352A1 (fr) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated Pyrid-2-ones disubstituees en 3, 5 inhibitrices de la famille tec des tyrosine kinases non receptrices
AU2006285145A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-.receptor tyrosine kinases
EP1919891B1 (fr) 2005-08-29 2012-03-07 Vertex Pharmaceuticals Incorporated Pyrid-2-ones 3,5-bisubstitues utiles en tant qu'inhibiteurs de la famille tec des tyrosines kinases depourvues de la fonction recepteur
WO2007026720A1 (fr) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Derive de pyrazole a noyau condense
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (fr) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. 2-amino-1-(4-fluorophenyl) éthanol optiquement actif
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (fr) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Dérivés tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques
WO2008025526A1 (fr) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Dérivés d'indole, fabrication de ceux-ci et utilisation comme agents pharmaceutiques
EP2559771A3 (fr) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Bio-marqueurs et méthodes pour déterminer la sensibilité aux modulateurs du recepteur du facteur de croissance de l'insuline (IGF1R).
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CN101687840A (zh) 2007-06-25 2010-03-31 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的苯并咪唑酰胺基衍生物
EP2065380A1 (fr) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Dérivés de pyridoneamide comme inhibiteurs de focal adhesion kinase (FAK) et leur utilisation pour le traitement du cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CA2712959C (fr) * 2008-01-22 2015-06-23 Vernalis (R & D) Ltd Derives d'indolyl-pyridone
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
MY160006A (en) 2008-12-19 2017-02-15 Sirtris Pharmaceuticals Inc Thiazolopyridine sirtuin modulating compounds
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
CN102459265A (zh) * 2009-05-27 2012-05-16 雅培制药有限公司 激酶活性的嘧啶抑制剂
WO2011053779A2 (fr) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r
US20130196990A1 (en) * 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
WO2012061169A1 (fr) * 2010-11-01 2012-05-10 Boehringer Ingelheim International Gmbh Inhibiteurs benzimidazole de production de leucotriènes
WO2013056069A1 (fr) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
WO2015004534A2 (fr) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
AU2014298051B2 (en) 2013-07-31 2018-11-15 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
CN103936719A (zh) * 2014-05-14 2014-07-23 中国药科大学 苯并咪唑类衍生物制备方法及用途
WO2016016894A1 (fr) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Milieux pour la culture de cellules souches pluripotentes
WO2016087936A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Pyridinones substituées utilisées comme inhibiteurs de bromodomaines
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (fr) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibiteurs de bromodomaines
CA2982664A1 (fr) * 2015-04-16 2016-10-20 Merck Patent Gmbh Derives de 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one
WO2020152686A1 (fr) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Milieux de culture pour cellules souches pluripotentes
CN117069696B (zh) * 2023-08-17 2024-04-26 中国药科大学 一种双靶点小分子抑制剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001000610A1 (fr) * 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Benzimidazoles substitues
WO2004031401A2 (fr) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Nouveaux inhibiteurs de tyrosine kinases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001000610A1 (fr) * 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Benzimidazoles substitues
WO2004031401A2 (fr) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Nouveaux inhibiteurs de tyrosine kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATZ B A ET AL: "A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 307, no. 5, 13 April 2001 (2001-04-13), pages 1451 - 1486, XP004466071, ISSN: 0022-2836 *
See also references of WO02079192A1 *

Also Published As

Publication number Publication date
IS6968A (is) 2003-09-26
NO20034308D0 (no) 2003-09-26
YU84603A (sh) 2006-03-03
PE20021015A1 (es) 2002-11-10
NO20034308L (no) 2003-11-26
CA2442428A1 (fr) 2002-10-10
BR0208373A (pt) 2005-02-22
SK12002003A3 (en) 2004-10-05
EE200300475A (et) 2004-02-16
PL373300A1 (en) 2005-08-22
KR20030083016A (ko) 2003-10-23
CZ20032615A3 (en) 2004-03-17
BG108206A (bg) 2004-11-30
GEP20053660B (en) 2005-11-10
HUP0400323A2 (hu) 2005-11-28
CN1514833A (zh) 2004-07-21
IL158041A0 (en) 2004-03-28
JP2004534010A (ja) 2004-11-11
EP1381598A1 (fr) 2004-01-21
AR035804A1 (es) 2004-07-14
MXPA03008690A (es) 2003-12-12
ZA200307466B (en) 2005-01-13
UY27234A1 (es) 2002-10-31
HRP20030844A2 (en) 2005-08-31
RU2003131693A (ru) 2005-05-10
WO2002079192A1 (fr) 2002-10-10

Similar Documents

Publication Publication Date Title
EP1381598A4 (fr) Nouveaux inhibiteurs de la tyrosine kinase
AU2003299651A8 (en) Tyrosine kinase inhibitors
EG24381A (en) Tyrosine kinase inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
EP1581539A4 (fr) Nouveaux inhibiteurs de tyrosine kinase
IL151104A0 (en) Kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
PL395096A1 (pl) Inhibitory kinaz tyrozynowych
IL161516A0 (en) Benzimidazoles useful as protein kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
EP1390052A4 (fr) Inhibition de la kinase jun
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
GB0101686D0 (en) Cyclin dependent kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
GB0201384D0 (en) Tyrosine kinase inhibitors
HK1060577A (en) Novel tyrosine kinase inhibitors
AU2002304001A1 (en) Tyrosine kinase inhibitors
AU2002327342A1 (en) Tyrosine kinase inhibitors
AU2002355733A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060577

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20080218

17Q First examination report despatched

Effective date: 20091124

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1060577

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120724